Bisphosphonates: Preclinical review

Oncologist

Volumn 9, Issue SUPPL. 4, 2004, Pages 3-13

  Green, Jonathan R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antitumor effects; Apoptosis; Bisphosphonates; Bone resorption; Mevalonate pathway; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BETA5 INTEGRIN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE; CLODRONIC ACID; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GERANYLTRANSFERASE; IBANDRONIC ACID; IMATINIB; MATRIGEL; MATRIX METALLOPROTEINASE; NITROGEN DERIVATIVE; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; TAXANE DERIVATIVE; UFT; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CELL CULTURE; CELL ADHESION; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; OSTEOCLAST; OSTEOSARCOMA; PANCREAS CANCER; PRENYLATION; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

EID: 5444242637     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90004-3     Document Type: Conference Paper

References (81)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-34.
2. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(suppl 2):S66-S80.
3. Stronski SA, Bettschen-Camin L, Wetterwald A et al. Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 1988;42:248-254.
4. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-415.
5. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(suppl 12):2961-2978.
6. Sato M, Grasser W, Endo N et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
7. Aparicio A, Gardner A, Tu Y et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-229.
8. Derenne S, Amiot M, Barille S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
9. Hiraga T, Williams PJ, Mundy GR et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-4424.
10. Lee MV, Fong EM, Singer FR et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
11. Mackie PS, Fisher JL, Zhou H et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-958.
12. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
13. Shipman CM, Rogers MJ, Apperley JF et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 1997;98:665-672.
14. Shipman CM, Croucher PI, Russell RG et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-5297.
15. Sonnemann J, Eckervogt V, Truckenbrod B et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-465.
16. Takahashi R, Shimazaki C, Inaba T et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001;25:77-83.
17. Tassone P, Tagliaferri P, Viscomi C et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003;88:1971-1978.
18. Rogers MJ, Russell RG, Blackburn GM et al. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992;189:414-423.
19. Rogers MJ, Ji X, Russell RG et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994;303:303-311.
20. Pelorgeas S, Martin JB, Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1, 1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study. Biochem Pharmacol 1992;44:2157-2163.
21. Frith JC, Mönkkönen J, Blackburn GM et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-1367.
22. Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-1262.
23. Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer 1997;80(suppl 8):1652-1660.
24. Selander KS, Monkkonen J, Karhukorpi EK et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-1138.
25. Gober HJ, Kistowska M, Angman L et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-168.
26. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
27. Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24(suppl 5):73S-79S.
28. Russell RG, Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14(suppl 2):53-65.
29. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-1487.
30. Luckman SP, Coxon FP, Ebetino FH et al. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-1678.
31. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta 1999;1423:C19-C30.
32. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996;65:241-269.
33. Alakangas A, Selander K, Mulari M et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70:40-47.
34. Mönkkönen H, Lehenkari PP, Kellinsalmi M et al. A new mechanism of action for bisphosphonates: apppi dedicated cytotoxicity of N-BPs. Bone 2004;34:S66-S67.
35. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-242.
36. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
37. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796.
38. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29(suppl 21):33-42.
39. Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-1134.
40. Corey E, Brown LG, Quinn JE et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003;9:295-306. Erratum in: Clin Cancer Res 2003;9:1574-1575.
41. Oades GM, Senaratne SG, Clarke IA et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003;170:246-252.
42. Matsumoto S, Kimura S, Segawa H et al. Efficacy of combining the third generation bisphosphonate, zoledronate with imatinib mesylate in suppressing small cell lung cancer cell line proliferation. Proc Am Soc Clin Oncol 2003;22:684.
43. Neville-Webbe HL, Evans CA, Coleman RE et al. Zoledronic acid (ZOL) in combination with doxorubicin (DOX) has synergistic effects on apoptosis of breast cancer cells (BCCs) in vitro [abstract]. Presented at the IVth International Conference on Cancer-Induced Bone Diseases, December 7-9, 2003, San Antonio, TX.
44. Tassone P, Forciniti S, Galea E et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-844.
45. Ullén A, Lennartsson L, Hjelm-Eriksson M et al. Additive/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronate [poster]. Presented at the European Winter Oncology Conference (EWOC-8), January 19-24, 2003, Flims, Switzerland.
46. Ullén A, Lennartsson L, Hjelm-Eriksson M et al. Additive/synergistic anti-tumoral effect on prostate cancer cells in vitro following treatment with a combination of gemcitabine and zoledronic acid. Proc Am Soc Clin Oncol 2003;22:432.
47. Vogt U, Wassmann K, Bosse U et al. Enhancement of breast tumor growth inhibition (BTGI) in vitro through combination of CMF, epirubicin/ cyclophosphamide (EC), epirubicin/paclitaxel (ET) and epirubicin/docetaxel (EDoc) with ibandronate (IB) or zoledronic acid (ZOL). Proc Am Soc Clin Oncol 2003;22:55.
48. Witters L, Crispino J, Javeed M et al. Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc Am Soc Clin Oncol 2002;21:5b.
49. Witters LM, Crispino J, Fraterrigo T et al. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003;26:S92-S97.
50. Schlotter CM, Vogt U, Bosse U et al. Enhancement of breast tumor growth inhibition (BTGI) in vitro through combination of CMF, epirubicin/ cyclophosphamide (EC), and epirubicin/paclitaxel (ET) with ibandronate (IB) or zoledronic acid (ZOL). J Bone Miner Res 2001;16(suppl 1):S191.
51. + leukemia activity of imatinib mesylate. Blood 2003;102:2229-2235.
52. Yaccoby S, Pearse RN, Johnson CL et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
53. Croucher PI, De Raeve H, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492.
54. Green J, Gschaidmeier H, Yoneda T et al. Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 2000;11(suppl 4):14.
55. Peyruchaud O, Winding B, Pecheur I et al. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-2034.
56. Hiraga T, Ueda A, Tamura D et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003;106:973-979.
57. Nobuyuki H, Hiraga T, Williams PJ et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res 2001;16(suppl 1):S191.
58. Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol 2002;14:609-615.
59. Cruz JC, Alsina M, Craig F et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001;29:441-447.
60. Alvarez E, Westmore M, Galvin RJ et al. Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res 2003;9:5705-5713.
61. Michigami T, Hiraga T, Williams PJ et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002;75:249-258.
62. Padalecki SS, Carreon M, Grubbs B et al. Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid. Oncology 2003;17(suppl):32.
63. Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif Tissue Int 2003;73:315-318.
64. Benford HL, McGowan NWA, Helfrich MH et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-473.
65. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-2221.
66. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-1486. Erratum in: Br J Cancer 2002;87:1340.
67. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
68. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-3894.
69. Magnetto S, Boissier S, Delmas PD et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-269.
70. van der Pluijm G, Vloedgraven H, van Beek E et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
71. Teronen O, Heikkila P, Konttinen YT et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 1999;878:453-465.
72. Heikkila P, Teronen O, Moilanen M et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002;13:245-254.
73. Pickering LM, Mansi JL, Colston KW. Adhesion of breast cancer cells to extracellular matrices is inhibited by zoledronic acid and enhanced by aberrant Ras signalling. Proc Am Soc Clin Oncol 2003;22:863.
74. Virtanen SS, Väänänen HK, Härkönen PL et al. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-2714.
75. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
76. Fournier P, Boissier S, Filleur S et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
77. Bonjean K, Bellahcene A, Locigno R et al. Zoledronate modulates endothelial cell surface receptors involved in angiogenesis. Proc Am Assoc Cancer Res 2001;42:106.
78. Bezzi M, Hasmim M, Bieler G et al. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death. Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 2003;278:43603-43614.
79. Pécheur I, Peyruchaud O, Serre CM et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-1268.
80. 3 antagonist (S247) inhibits MDA-MB-435 breast cancer metastasis to bone. Oncology 2003;17(suppl):18.
81. Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-2897.